Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIRST study of niraparib plus dostarlimab with platinum-based first-line therapy in advanced nonmucinous epithelial ovarian cancer
2024-510605-28-00Phase 3Authorised
- Sponsor
- TESARO, Inc.
- Start
- Apr 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 19
01
Overview
Phase 3, randomised, double-blind trial of dostarlimab and niraparib in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by TESARO, Inc. Primary endpoint: Progression-free survival. Planned start Apr 2024; status: authorised.
02
Drugs
dostarlimabniraparib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2024-510605-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510605-28-00.